Synopsis & toc Epilepsy drugs market in india

Disclaimer: All information contained in this report has been obtained from sources believed to be accurate by Gyan Research and Analytics (Gyan). While

reasonable care has been taken in its preparation, Gyan makes no representation or warranty, express or implied, as to the accuracy, timeliness or

completeness of any such information. The information contained herein may be changed without notice. All information should be considered solely as

statements of opinion and Gyan will not be liable for any loss incurred by users from any use of the publication or contents.

Epilepsy Drug

Market in India:

(2014-2018)

Epilepsy Drugs Market in India: (2014-2018)

2 | P a g e

© Gyan Research and Analytics Pvt. Ltd., 2014

Synopsis

According to Global Business Intelligence, the global epilepsy drugs revenue was worth USD 4.1

billion in 2011. The estimated global market size of epilepsy drugs in 2013 was USD 4.28 billion. With

a Compound Annual Growth Rate (CAGR) of 2 percent through 2009-2018, it is expected to clock a

turnover of USD 4.73 billion in 2018. The epilepsy drug market accrued revenue worth USD 1.1

billion in 2012. It was estimated to reach to USD 1.16 billion in 2013 with a CAGR of 5 percent

throughout 2009-2013. Majority of this share was accounted by Australia, China, India and Japan.

India with over 1 billion population is likely to have more than a million patients with epilepsy.

According to Times of India, around 14 people per 1,000 population are expected to suffer from

epilepsy. Epilepsy is more prevalent among children and young adults and in the rural areas. In India

about 95 percent of epileptic patients do not receive any treatment. With a CAGR of 15 percent

throughout 2009-2013, the market size of anti-epileptic drugs was estimated at USD 164.93 million

in 2013.

Since the research and development associated with the innovation of new anti-epileptic drugs are

costly, the rate of innovation in much low in India. The probability of successful innovation of AED is

even less than 10 percent. Moreover, these cases of research process are associated with high

investment with lack of safety and efficacy. Thus, proper monitoring is required in order to bring in

innovative drugs into the market.

Emergence of new anti-epileptic drugs and awareness of the disease among the Indians can serve

better prospects for the market to develop. With companies like Johnson & Johnson,

GlaxoSmithKline, Abbott, Cephalon and many others operating in the country, the market for the

anti-epileptic drugs is expected to grow in future and reach revenue worth USD 208.69 million in

2019.


3 | P a g e


Table of Content

1. Global Epilepsy Drugs Market

2. Epilepsy Drugs Market in Asia-Pacific (APAC)

3. Epilepsy Drug Market in India

4. Major Trends

4.1 High Cost of Treatment

4.2 Large Number of Patients devoid of Treatment

4.3 High Rate of Epilepsy Prevalence in Some Cities

4.4 High Number of Patients

4.5 Pregnancy and Epilepsy

4.6 Epilepsy and Educational Problem

4.7 Introduction of New Smartphone Apps to Detect Epilepsy

4.8 Economic Failure of Anti- Epileptic Drugs

5. Outlook


4 | P a g e


GYAN RESEARCH AND ANALYTICS PVT. LTD.

Corporate Office:

LG 37-38, Ansal Fortune Arcade, Sector-18,

Noida- 201 301

Delhi NCR, INDIA

Phone: +91-120-4235181

Regd. Office:

298-A, Pocket 2

Mayur Vihar Phase -1

Delhi 110 091, INDIA

Central Delivery Centre:

BD-9, Sector-1,

Salt Lake City

Kolkata- 700 064, INDIA

Phone: +91-33-40060084

E-mail: [email protected]

Website: www.gyananalytics.com

Health & Medicine

Synopsis & toc Epilepsy drugs market in india